Current application of "high-dose" @entity134 therapy for XXXX . A pharmacological perspective.

@entity1 @entity149 @entity134 @entity230 @entity130
Although administration of glucocorticoid @entity230 is one of the most widely used therapeutic modalities for the clinical management of acute @entity149 (CNS), controversy continues regarding their effectiveness. In essence, two viewpoints concerning their use exist. Some believe that despite their poor clinical record, the @entity230 nevertheless have a place in the treatment of @entity1 CNS @entity130 . In general, this group of clinical investigators uses the @entity230 primarily out of tradition, feeling that @entity134 therapy may be of some benefit. Unfortunately, confusion remains as to what constitutes an appropriate dose or regimen. In this regard, it has been suggested that the @entity134 dose be increased and the regimen intensified. Others believe that @entity230 should not be used. They contend that in view of their poor clinical record, it is unlikely that increasing the @entity134 dose or changing the dosing regimen will improve clinical efficacy, since @entity230 have already failed at what may be considered huge doses by glucocorticoid standards. Furthermore, it is contended that the side effects associated with large @entity134 doses reduce the margin of safety so as to make the @entity230 unsafe. Complicating these arguments is a body of experimental evidence that by and large strongly supports the utility of @entity230 for the acute treatment of CNS @entity130 . The intent of this article is to evaluate the current use of @entity134 therapy for CNS @entity130 from a purely pharmacological perspective, and to compare the @entity230 ' experimental use with their clinical application.
